Review



vegfc  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems vegfc
    Vegfc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 34 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+vegf+c/pm41944190-231-16-17?v=R%26D+Systems
    Average 94 stars, based on 34 article reviews
    vegfc - by Bioz Stars, 2026-07
    94/100 stars

    Images



    Similar Products

    mouse recombinant vegfc  (MedChemExpress)
    94
    MedChemExpress mouse recombinant vegfc
    Mouse Recombinant Vegfc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+vegf+c/pm42044813-65-13-16?v=MedChemExpress
    Average 94 stars, based on 1 article reviews
    mouse recombinant vegfc - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    vegfc  (R&D Systems)
    94
    R&D Systems vegfc
    Vegfc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+vegf+c/pm41944190-231-16-17?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    vegfc - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    purified recombinant rat vegf c protein 152s  (Biosynth Carbosynth)
    94
    Biosynth Carbosynth purified recombinant rat vegf c protein 152s
    VEGF-C <t>152s</t> treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
    Purified Recombinant Rat Vegf C Protein 152s, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+vegf+c/pmc13012992-75-20-26?v=Biosynth+Carbosynth
    Average 94 stars, based on 1 article reviews
    purified recombinant rat vegf c protein 152s - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    recombinant human vegf c c156s  (R&D Systems)
    94
    R&D Systems recombinant human vegf c c156s
    VEGF-C <t>152s</t> treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
    Recombinant Human Vegf C C156s, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+vegf+c/pm41797259-55-0-4?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    recombinant human vegf c c156s - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    recombinant vegf c protein  (Novoprotein)
    86
    Novoprotein recombinant vegf c protein
    VEGF-C <t>152s</t> treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
    Recombinant Vegf C Protein, supplied by Novoprotein, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+vegf+c/10__3390_slash_cimb48030259-194-0-14?v=Novoprotein
    Average 86 stars, based on 1 article reviews
    recombinant vegf c protein - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    recombinant vegf c cys156ser protein  (R&D Systems)
    94
    R&D Systems recombinant vegf c cys156ser protein
    VEGF-C <t>152s</t> treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
    Recombinant Vegf C Cys156ser Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+vegf+c/bio_rxiv__64898__2026__01__28__702461-134-12-22?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    recombinant vegf c cys156ser protein - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    human vegf standard  (R&D Systems)
    94
    R&D Systems human vegf standard
    VEGF-C <t>152s</t> treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
    Human Vegf Standard, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+vegf+c/pmc13058789-188-20-23?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    human vegf standard - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    recombinant human vegf c  (Upstate Biotechnology Inc)
    86
    Upstate Biotechnology Inc recombinant human vegf c
    VEGF-C <t>152s</t> treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
    Recombinant Human Vegf C, supplied by Upstate Biotechnology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+vegf+c/pm41530276-218-0-3?v=Upstate+Biotechnology+Inc
    Average 86 stars, based on 1 article reviews
    recombinant human vegf c - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    VEGF-C 152s treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

    Journal: Frontiers in Cardiovascular Medicine

    Article Title: Sex-specific lymphatic responses to estrogen shape atherosclerosis in high-risk mice

    doi: 10.3389/fcvm.2026.1699372

    Figure Lengend Snippet: VEGF-C 152s treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

    Article Snippet: Mice received intraperitoneal (IP) injections of VEGF-C (152s) at a dose of 50 ng per 25 g of body weight [purified recombinant rat VEGF-C protein (152s), Fitzgerald, catalog no. 30R-AV006-22] or vehicle control (phosphate-buffered saline, PBS), administered three times per week for four consecutive weeks.

    Techniques: Clinical Proteomics, Intravital Microscopy, Staining